Fluticasone Furoate

also known as GW685698X · FFNS · GW685698 · Avamys · Fluticasone furoate nasal spray · VERAMYST · ALLERMIST · AVAMYS (TM)

Other / unclassified

Developed for: asthma · chronic obstructive pulmonary disease · perennial allergic rhinitis · seasonal allergic rhinitis · allergic rhinitis · vasomotor rhinitis · respiratory system disorder · rhinitis
+4 more
· sinusitis · eye allergy · nasal cavity polyp · obstructive sleep apnea syndrome
Investigated by: GlaxoSmithKline · Parexel · Morten Hostrup, PhD · Sandoz · University of Chicago · University of Saskatchewan
+20 more
· Assaf-Harofeh Medical Center · BI Medical.Inc. · Baylor Research Institute · Bispebjerg Hospital · Dr. Grace Parraga · Hammersmith Medicines Research · Maastricht University Medical Center · Norwegian University of Science and Technology · Q2 Solutions · Rigshospitalet, Denmark · SRL Medisearch Inc. · St. Olavs Hospital · University of British Columbia · University of Calgary · University of Manitoba · University of North Carolina, Chapel Hill · University of Ottawa · Western Sky Medical Research · Western University, Canada · York Bioanalytical Solution

Regulatory milestones approvals, filings & regulatory actions · 11 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Filed asthma 2 milestones
Filed	EU (EMA)	Relvar Ellipta	asthma	2017-07-21	“submission to the European Medicines Agency (EMA) for the extended use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI)” gsk.com ↗
Filed	US (FDA)	—	asthma	2013-10-23	“today announced the submission of a New Drug Application (NDA) in the US for the once daily inhaled corticosteroid (ICS) treatment, fluticasone furoate (FF)” gsk.com ↗
Filed chronic obstructive pulmonary disease 3 milestones
Filed	EU (EMA)	—	chronic obstructive pulmonary disease	2016-12-02	“filing by GSK of a regulatory submission with the European Medicines Agency for once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol” gsk.com ↗
Filed	US (FDA)	—	chronic obstructive pulmonary disease	2016-11-21	“filing by GSK of a regulatory submission with the US Food and Drug Administration for the once-daily, closed triple combination therapy fluticasone furoate/umeclidinium/vilanterol” gsk.com ↗
Filed	US (FDA)	—	chronic obstructive pulmonary disease	2012-09-26	“for patients with chronic obstructive pulmonary disease (COPD), has been accepted by the US Food and Drug Administration (FDA)” gsk.com ↗
Approved Indication not stated 4 milestones
Label expansions (2)	US (FDA)	ARNUITY ELLIPTA	—	2018-05-17 – 2023-03-01	fda.gov ↗
Label expansions (2)	US (FDA)	FLONASE SENSIMIST ALLERGY RELIEF	—	2012-08-21 – 2016-08-02	fda.gov ↗
Approved	EU (EMA)	Avamys	—	2008-01-11	europa.eu ↗
Approved	US (FDA)	FLONASE SENSIMIST ALLERGY RELIEF	—	2007-04-27	fda.gov ↗

Trials 126 · started per year

today

US approved 2007

EU approved 2008

20032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 121 trials
Phase 1	NCT02837380	Sep → Nov 2016	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT02666287	Jan → Jun 2016	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT02064504	Feb → May 2014	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01837316	Oct 2013 → Aug 2014	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01962467	Oct 2013 → Feb 2014	allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01894386	Jul → Sep 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01691547	Dec 2012 → Mar 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01711463	Dec 2012 → Jun 2013	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01725685	Nov 2012 → Jan 2013	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01669070	Aug → Nov 2012	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01266980	Nov 2010 → Mar 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01213849	Oct → Nov 2010	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01165125	Jul → Aug 2010	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01209026	Jun 2010 → Jan 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01299558	May → Jul 2010	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT01000597	Sep → Dec 2009	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00972673	Sep → Dec 2008	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00538057	Oct → Dec 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00444509	Feb → Apr 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00522678	Feb → Apr 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT00419237	Jan → Apr 2005	asthma	GlaxoSmithKline	Completed	No outcome recorded

Phase 215 trials · 9 met primary
Phase 2	NCT03739294	Feb 2019 → Dec 2020	—	Bispebjerg Hospital	Completed	No outcome recorded
Phase 2	NCT02991859	Feb 2017 → Dec 2018	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT02712047	Apr 2016 → Feb 2017	asthma	GlaxoSmithKline	Completed	Met primary
Phase 2	NCT02573870	Dec 2015 → Jul 2016	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT02164539	Jul 2014 → Jul 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 2	NCT01957202	Oct 2013 → Feb 2014	allergic rhinitis	GlaxoSmithKline	Completed	Met primary
Phase 2	NCT01808339	Mar 2013 → Mar 2014	asthma	GlaxoSmithKline	Completed	Met primary
Phase 2	NCT01287065	Oct 2010 → Sep 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01018030	Jan → Jul 2010	sinusitis	GlaxoSmithKline	Completed	Met primary
Phase 2	NCT00766090	Oct 2008 → Mar 2009	asthma	GlaxoSmithKline	Completed	Met primary
Phase 2	NCT00603382	Dec 2007 → Oct 2008	asthma	GlaxoSmithKline	Completed	Met primary
Phase 2	NCT00603746	Dec 2007 → Sep 2008	asthma	GlaxoSmithKline	Completed	Met primary
Phase 2	NCT00603278	Dec 2007 → Nov 2008	asthma	GlaxoSmithKline	Completed	Met primary
Phase 2	NCT00398645	Nov 2006 → Aug 2007	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01499446	Sep 2003 → Mar 2004	asthma	GlaxoSmithKline	Completed	No outcome recorded

Phase 360 trials · 25 met primary · 10 missed
Phase 3	NCT07223294	Apr 2026	respiratory system disorder	Sandoz	Withdrawn	No outcome recorded Stop: Business
Phase 3	NCT04651777	Aug 2022 → Aug 2023 overdue	asthma	Dr. Grace Parraga	Active not recruiting	No outcome recorded
Phase 3	NCT03376932	Jan 2019 → Feb 2021	asthma	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 3	NCT03248128	Oct 2017 → Mar 2022	asthma	GlaxoSmithKline	Completed	Mixed
Phase 3	NCT03184987	Jun 2017 → Jun 2019	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02924688	Oct 2016 → Feb 2019	asthma	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT02729051	Jun 2016 → May 2017	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02483975	Oct 2015 → Jun 2016	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT02502734	Sep → Dec 2015	asthma	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT02446418	Jul 2015 → Jul 2017	asthma	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT02301975	Mar 2015 → Nov 2016	asthma	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT02345161	Jan 2015 → Apr 2016	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Mixed
Phase 3	NCT02164513	Jun 2014 → Jul 2017	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT02105974	Apr 2014 → Jul 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT02094937	Mar 2014 → Aug 2015	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01706198	Nov 2012 → Dec 2016	asthma	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01691885	Nov 2012 → Jul 2014	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01706328	Oct 2012 → Jun 2013	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Missed primary
Phase 3	NCT01686633	Sep 2012 → Oct 2013	asthma	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01622231	Jun → Nov 2012	rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01630135	Jun → Aug 2012	perennial allergic rhinitis	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01551758	Mar 2012 → Nov 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01498653	Jan 2012 → Feb 2013	asthma	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01431950	Sep 2011 → Oct 2012	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01436071	Sep 2011 → Jun 2012	asthma	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01436110	Sep 2011 → Sep 2012	asthma	GlaxoSmithKline	Completed	Missed primary
Phase 3	NCT01395888	Jun 2011 → Aug 2012	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Missed primary
Phase 3	NCT01323621	Mar 2011 → Jan 2012	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Missed primary
Phase 3	NCT01323634	Mar → Dec 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01336608	Mar 2011 → Nov 2014	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Missed primary
Phase 3	NCT01342913	Feb → Oct 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Missed primary
Phase 3	NCT01313676	Jan 2011 → Jul 2015	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Missed primary
Phase 3	NCT01279057	Dec 2010 → Feb 2011	seasonal allergic rhinitis	Sandoz	Completed	Met primary
Phase 3	NCT01165138	Aug 2010 → Oct 2011	asthma	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01192191	Aug 2010 → Jan 2012	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01244984	Jul 2010 → Jan 2012	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01159912	Jun 2010 → Jan 2012	asthma	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01147848	Jun 2010 → Jul 2011	asthma	GlaxoSmithKline	Completed	Missed primary
Phase 3	NCT01086384	Feb 2010 → Sep 2011	asthma	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01072149	Jan → Jul 2010	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01018186	Oct 2009 → May 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01054885	Oct 2009 → Feb 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01017952	Sep 2009 → Oct 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01009463	Sep 2009 → Oct 2011	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Mixed
Phase 3	NCT01231464	Sep 2009 → May 2010	perennial allergic rhinitis	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT00289198	Feb → Jul 2006	perennial allergic rhinitis	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT00224523	Sep 2005 → Feb 2007	perennial allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00197262	Aug → Oct 2005	seasonal allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00117325	Jul 2005 → Feb 2006	vasomotor rhinitis	GlaxoSmithKline	Completed	Missed primary
Phase 3	NCT00118703	Jul 2005 → Feb 2006	vasomotor rhinitis	GlaxoSmithKline	Completed	Missed primary
Phase 3	NCT00225823	May → Aug 2005	seasonal allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00109486	Apr → Nov 2005	allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00118729	Apr → Aug 2005	seasonal allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00107757	Mar → Nov 2005	perennial allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00363740	Feb → Apr 2005	seasonal allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00116883	Feb → Jul 2005	perennial allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT00108914	Feb → Nov 2005	perennial allergic rhinitis	GlaxoSmithKline	Completed	Mixed
Phase 3	NCT00116818	Jan → May 2005	perennial allergic rhinitis	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT00103454	Jan → May 2005	perennial allergic rhinitis	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT00115622	Dec 2004 → Jan 2005	seasonal allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded

Phase 426 trials · 8 met primary · 3 missed
Phase 4	NCT07192016	Mar 2026 → Sep 2027 expected	chronic obstructive pulmonary disease	Western University, Canada	Not yet recruiting	No outcome recorded
Phase 4	NCT06552364	Apr 2025 → Dec 2026 expected	chronic obstructive pulmonary disease	University of British Columbia	Not yet recruiting	No outcome recorded
Phase 4	NCT06372496	Apr 2024 → Jul 2025 overdue	asthma	GlaxoSmithKline	Active not recruiting	No outcome recorded
Phase 4	NCT04923347	Jun 2023 → Mar 2024	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT05651750	Nov 2022 → May 2023	—	Assaf-Harofeh Medical Center	Unknown	No outcome recorded
Phase 4	NCT05535972	Oct 2022 → Sep 2023	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT05292053	Jul 2022 → Sep 2024	chronic obstructive pulmonary disease	Baylor Research Institute	Completed	No outcome recorded
Phase 4	NCT03949842	Jun 2019 → Nov 2022	chronic obstructive pulmonary disease	GlaxoSmithKline	Withdrawn	No outcome recorded Stop: Enrollment
Phase 4	NCT03898466	Oct 2018 → Apr 2019	asthma	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT03478696	Jun 2018 → Mar 2019	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03467425	Apr 2018 → Oct 2019	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT03474081	Mar 2018 → Jul 2019	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT03315000	Oct 2017 → May 2018	asthma	University of Saskatchewan	Completed	No outcome recorded
Phase 4	NCT02889809	Jul 2017 → Apr 2021	asthma	GlaxoSmithKline	Completed	Missed primary
Phase 4	NCT02730351	May 2016 → Feb 2017	asthma	GlaxoSmithKline	Completed	Missed primary
Phase 4	NCT02424539	Sep 2015 → Oct 2017	perennial allergic rhinitis	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT02397915	Mar → Jun 2015	allergic rhinitis	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT01957150	Jan 2014 → Mar 2018	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00997620	Mar → Sep 2010	seasonal allergic rhinitis	Western Sky Medical Research	Completed	No outcome recorded
Phase 4	NCT01007253	Nov 2009 → Apr 2010	seasonal allergic rhinitis	University of Chicago	Completed	Met primary
Phase 4	NCT01270958	Aug 2009 → Feb 2010	perennial allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00609674	Jan → Jun 2008	perennial allergic rhinitis	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT00570492	Nov 2007 → Mar 2011	perennial allergic rhinitis	GlaxoSmithKline	Completed	Missed primary
Phase 4	NCT00502775	Aug → Nov 2007	seasonal allergic rhinitis	GlaxoSmithKline	Completed	Met primary
Phase 4	NCT00473915	Apr → Dec 2007	seasonal allergic rhinitis	University of Chicago	Completed	No outcome recorded
Phase 4	NCT00435461	Dec 2006 → Feb 2007	seasonal allergic rhinitis	GlaxoSmithKline	Completed	Met primary

Phase not applicable4 trials
—	NCT06066606	Oct 2023 → Jul 2026 overdue	—	Morten Hostrup, PhD	Recruiting	No outcome recorded
—	NCT06077019	Oct 2023 → Jul 2026 overdue	—	Morten Hostrup, PhD	Recruiting	No outcome recorded
—	NCT01562093	Jan 2012 → Jun 2016	asthma	St. Olavs Hospital	Terminated	No outcome recorded
—	NCT01318681	Jan 2011 → Mar 2012	seasonal allergic rhinitis	Maastricht University Medical Center	Completed	No outcome recorded
Comparator or background therapy39 trials
Phase 0	NCT05381207 Comparator	Oct 2022 → Oct 2024	allergic rhinitis	Assiut University	Unknown	No outcome recorded
Phase 1	NCT02218723 Comparator	Oct → Dec 2014	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 1/2	NCT05143502 Background	Jan 2022 → Jan 2024	chronic rhinosinusitis	Assiut University	Unknown	No outcome recorded
Phase 2	NCT04072887 Background	Sep 2019 → Oct 2021	chronic obstructive pulmonary disease	Novartis Pharmaceuticals	Completed	Missed primary
Phase 2	NCT03622112 Comparator	Jan → Sep 2019	asthma	AstraZeneca	Completed	Missed primary
Phase 2	NCT03012061 Background	Jan 2017 → May 2018	asthma	GlaxoSmithKline	Completed	Met primary
Phase 2	NCT01573624 Comparator	Apr 2012 → Feb 2013	asthma	GlaxoSmithKline	Completed	Met primary
Phase 2	NCT01563029 Comparator	Mar 2012 → Sep 2014	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01453023 Comparator	Oct 2011 → Jun 2012	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01332292 Comparator	May 2010 → Jan 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01128595 Comparator	May 2010 → May 2011	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT01128569 Comparator	Jan → Oct 2010	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 2	NCT00730756 Comparator	Mar 2008 → Feb 2009	perennial allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT05757102 Background	Apr 2023 → Jan 2027 expected	asthma	GlaxoSmithKline	Recruiting	No outcome recorded
Phase 3	NCT05299086 Comparator	Apr 2022 → Mar 2025	perennial allergic rhinitis	Mahidol University	Completed	No outcome recorded
Phase 3	NCT05276336 Background	Jul 2018 → Feb 2020	allergic rhinitis	Indonesia University	Completed	No outcome recorded
Phase 3	NCT02731846 Background	Jun → Nov 2016	chronic obstructive pulmonary disease	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 3	NCT02467452 Comparator	May 2015 → Jan 2017	chronic obstructive pulmonary disease	Chiesi Farmaceutici S.p.A.	Completed	No outcome recorded
Phase 3	NCT01957163 Background	Oct 2013 → Apr 2014	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT02119286 Background	Oct 2013 → Apr 2014	chronic obstructive pulmonary disease	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT01498679 Comparator	Jan 2012 → Jul 2013	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 3	NCT01435902 Comparator	Jan → Aug 2012	asthma	GlaxoSmithKline	Withdrawn	No outcome recorded Stop: Enrollment
Phase 3	NCT01134042 Comparator	Jun 2010 → Oct 2011	asthma	GlaxoSmithKline	Completed	Met primary
Phase 3	NCT00398476 Comparator	Dec 2006	perennial allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT03363191 Comparator	Mar 2018 → May 2019	asthma	GlaxoSmithKline	Withdrawn	No outcome recorded
Phase 4	NCT03380429 Background	Jan 2018 → Jan 2019	asthma	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT05342558 Comparator	Sep 2017 → Nov 2020	chronic obstructive pulmonary disease	National Institute of Respiratory Diseases, Mexico	Completed	No outcome recorded
Phase 4	NCT03152149 Comparator	Jun 2017 → Nov 2019	chronic obstructive pulmonary disease	University of Dundee	Completed	No outcome recorded
Phase 4	NCT01013701 Comparator	Nov 2009 → Jul 2010	nasal cavity polyp	Johns Hopkins University	Terminated	No outcome recorded
Phase 4	NCT00891436 Comparator	Apr → Jul 2009	eye allergy	Rush University Medical Center	Completed	No outcome recorded
Phase 4	NCT00791973 Comparator	Nov 2008 → Apr 2009	allergic rhinitis	University of Chicago	Completed	No outcome recorded
Phase 4	NCT00682643 Comparator	Jun 2008 → Feb 2011	perennial allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00603044 Comparator	Jan 2008 → Jan 2009	obstructive sleep apnea syndrome	University of Chicago	Completed	No outcome recorded
Phase 4	NCT00539006 Comparator	Aug → Nov 2007	perennial allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00519636 Comparator	Aug → Nov 2007	perennial allergic rhinitis	GlaxoSmithKline	Completed	No outcome recorded
Phase 4	NCT00584987 Comparator	Jun 2007 → Jul 2009	allergic rhinitis	University of Chicago	Completed	No outcome recorded
Phase 4	NCT01076439 Comparator	—	allergic rhinitis	ORA, Inc.	Withdrawn	No outcome recorded
—	NCT04621513 Background	Jul 2020 → Dec 2021	obstructive sleep apnea syndrome	China Medical University Hospital	Unknown	No outcome recorded
—	NCT03673384 Background	Mar 2015 → Jul 2017	allergic rhinitis	Nanhua University	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 38

Date	Issuer	Release
2026-01-23	GlaxoSmithKline	Regulatory Trelegy Ellipta approved in China for use in adults with uncontrolled asthma gsk.com ↗ The approval means that FF/UMEC/VI is the first and only single inhaler triple therapy (SITT) approved for the maintenance treatment of both respiratory conditions in the country.
2020-09-09	GlaxoSmithKline	Regulatory FDA approves Trelegy Ellipta as the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US gsk.com ↗ The FDA-approved strength for both COPD and asthma is fluticasone furoate / umeclidinium / vilanterol 100/62.5/25mcg.
2020-02-27	GlaxoSmithKline	Regulatory GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma gsk.com ↗ today announced the acceptance of a regulatory submission seeking an additional indication for the use of once-daily, single-inhaler triple therapy, Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI)
2018-05-29	GlaxoSmithKline	Regulatory GSK submits regulatory application in Japan for once-daily single inhaler triple therapy FF/UMEC/VI for patients with COPD gsk.com ↗ We are delighted to have filed a new drug application for the first single inhaler triple therapy for the treatment of COPD in Japan where the prevalence of COPD is of public concern.
2018-05-21	GlaxoSmithKline	Regulatory GSK receives US approval of Arnuity Ellipta for use in children from 5 years old who suffer from asthma gsk.com ↗ The approval is for the use of Arnuity Ellipta as maintenance treatment of asthma as prophylactic therapy in children aged 5 to 11 years, delivered as a 50mcg once-daily dose using the Ellipta inhaler.
2018-04-18	GlaxoSmithKline	Results Landmark IMPACT study published in NEJM shows significant benefits of Trelegy Ellipta for patients with COPD gsk.com ↗ A 42.1% reduction in the risk of on-treatment all-cause mortality was observed for Trelegy compared to Anoro (1.20% vs. 1.88%; p=0.011).
2018-03-08	GlaxoSmithKline	Regulatory GSK announces positive EU approval for labelling update to Relvar Ellipta in patients with asthma gsk.com ↗ We welcome this approval, which signifies an important milestone for Relvar Ellipta.
2018-02-15	Theravance Biopharma	Regulatory Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta theravance.com ↗ Theravance Biopharma, Inc. (NASDAQ: TBPH) (" Theravance Biopharma ") today highlighted the submission of the landmark IMPACT study data to the European Medicines Agency (EMA) as part of a type II variation to support an expanded label for Trelegy Ellipta in Europe for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD).
2018-01-26	GlaxoSmithKline	Regulatory GSK announces CHMP positive opinion for labelling update to Relvar Ellipta in patients with asthma gsk.com ↗ We are very excited about achieving this CHMP positive opinion which, if approved, provides an additional option for physicians, who can prescribe once-daily Relvar Ellipta for their asthma patients
2017-12-21	GlaxoSmithKline	Regulatory FDA approves US label update on ICS/LABA combinations in asthma, based on review of safety data gsk.com ↗ The FDA also approved updates to the Warnings and Precautions section of labelling for the ICS/LABA class.
2017-09-20	GlaxoSmithKline	Results GSK and Innoviva report positive headline results from IMPACT study showing single inhaler triple therapy Trelegy Ellipta reduced COPD exacerbations gsk.com ↗
2017-09-15	GlaxoSmithKline	Regulatory Trelegy Ellipta once-daily single inhaler triple therapy receives positive opinion from the CHMP in Europe for appropriate patients with COPD gsk.com ↗
2017-09-11	GlaxoSmithKline	Results Positive results from pioneering Salford Lung Study in asthma published in The Lancet, and presented at European Respiratory Congress gsk.com ↗ GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive results from the Salford Lung Study (SLS) in asthma have been simultaneously published in The Lancet journal and presented at the European Respiratory Society (ERS) International Congress in Milan.
2017-07-24	GlaxoSmithKline	Regulatory GSK submits US regulatory filing of Arnuity Ellipta in children with asthma gsk.com ↗ Today’s submission includes data from a pivotal study assessing the efficacy and safety of once daily fluticasone furoate, compared to placebo, in 593 children aged 5 to 11 years (inclusive) with asthma.
2017-05-05	GlaxoSmithKline	Results Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care gsk.com ↗ This open-label, randomised study showed that significantly more asthma patients initiated on treatment with Relvar Ellipta 100/25mcg or 200/25mcg (fluticasone furoate ‘FF’/vilanterol ‘VI’ or ‘FF/VI’) achieved an improvement in their asthma control compared with patients who continued to take their usual care medicines.
2017-02-23	GlaxoSmithKline	Results Positive results for Relvar® Ellipta® lung function study in patients with well-controlled asthma gsk.com ↗ In this positive study we have demonstrated non-inferiority for once-daily Relvar versus twice-daily Seretide on lung function.
2016-12-02	GlaxoSmithKline	Regulatory Relvar® Ellipta® 100/25 mcg gains approval in Japan for use in patients with COPD gsk.com ↗ today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar® Ellipta® (fluticasone furoate / vilanterol 100/25 mcg) for the relief of various symptoms with chronic obstructive pulmonary disease (chronic bronchitis, pulmonary emphysema) (in the case where concurrent use of inhaled corticosteroid and long-acting inhaled beta2 agonist is required).
2016-09-06	GlaxoSmithKline	Results GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress gsk.com ↗ In addition, the proportion of patients who responded with the minimum clinically important difference in SGRQ (-4 units) was 50% on closed triple and 41% on budesonide/formoterol (odds ratio 1.41; p<0.001).
2016-09-04	GlaxoSmithKline	Results GSK announce positive results from the COPD Salford Lung Study published in the NEJM and presented at European Respiratory Congress gsk.com ↗ A similar reduction in exacerbations with FF/VI was seen in those patients on an ICS/long-acting beta2-agonist (LABA) at baseline (8.0%; 95% CI 0.11 to 15.4, p=0.047).
2016-06-20	GlaxoSmithKline	Results FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in improving lung function and health-related quality of life in COPD patients gsk.com ↗
2016-05-24	GlaxoSmithKline	Results Salford Lung Study results show COPD patients treated with Relvar® Ellipta® achieve superior reduction in exacerbations compared with ‘usual care’ gsk.com ↗ The study showed that Relvar® Ellipta® 100/25mcg (fluticasone furoate ‘FF’/vilanterol ‘VI’ or ‘FF/VI’) achieved a superior reduction in exacerbations versus usual care, in patients with COPD, in an everyday clinical practice setting.
2015-09-24	GlaxoSmithKline	Results Regulatory update: GSK and Theravance announce intention to file Relvar® Ellipta® for COPD in Japan gsk.com ↗ The study which included 1620 patients with COPD, of whom 370 were from Japan, showed that patients who received FF/VI 100/25mcg achieved a statistically significant improvement in lung function (as measured by change from baseline in trough FEV1) compared with VI 25mcg at 12 weeks (p=0.001).
2015-04-30	GlaxoSmithKline	Regulatory FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US gsk.com ↗ Two strengths, 100/25mcg and 200/25mcg, have been approved in the US for use in asthma, administered once-daily using the Ellipta dry powder inhaler.
2015-03-19	GlaxoSmithKline	Regulatory GSK and Theravance announce outcome of US FDA Advisory Committee on BREO® ELLIPTA® in asthma gsk.com ↗ The FDA Advisory Committee voted that the efficacy and safety data for FF/VI 100/25 mcg and 200/25 mcg once daily in asthma support approval in adults 18 years of age and older (16 for, 4 against).
2014-09-08	GlaxoSmithKline	Results GSK data presented at ERS demonstrate potential of blood eosinophil levels to help inform COPD treatment decisions gsk.com ↗
2014-08-20	GlaxoSmithKline	Regulatory GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the USA for the treatment of asthma gsk.com ↗ GlaxoSmithKline plc today announced that the Food and Drug Administration has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older.
2014-06-30	GlaxoSmithKline	Regulatory GSK and Theravance announce submission to US regulatory authorities for fluticasone furoate/vilanterol in asthma gsk.com ↗
2013-12-06	GlaxoSmithKline	Results GSK and Theravance announce positive results from pivotal phase III study for fluticasone furoate/vilanterol in asthma gsk.com ↗ GlaxoSmithKline (GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from a phase III efficacy and safety study of fluticasone furoate “FF”/vilanterol “VI” designed to support a potential filing for an asthma indication for adults in the US.
2013-11-18	GlaxoSmithKline	Regulatory RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD gsk.com ↗
2013-10-23	GlaxoSmithKline	Regulatory GSK announces US regulatory submission for fluticasone furoate monotherapy for asthma gsk.com ↗ The NDA has been submitted to the US Food and Drug Administration (FDA) for FF monotherapy (100mcg and 200mcg doses) as a once-daily inhaled dry powder maintenance treatment of asthma as prophylactic therapy in patients aged 12 years and older.
2013-09-20	GlaxoSmithKline	Regulatory RELVAR™ ELLIPTA™ gains approval in Japan for the treatment of asthma gsk.com ↗ today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved RELVAR™ ELLIPTA™ for the treatment of bronchial asthma (in cases where concurrent use of inhaled corticosteroid and long-acting inhaled beta2 agonist is required).
2013-07-12	GlaxoSmithKline	Regulatory Regulatory update: fluticasone furoate/vilanterol submission in Japan gsk.com ↗ As a result, a decision has been taken to withdraw COPD from the current JNDA at this time.
2013-05-10	GlaxoSmithKline	Regulatory BREO™ ELLIPTA™ gains US approval for the treatment of COPD gsk.com ↗ GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved BREO™ ELLIPTA™ as an inhaled long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
2013-04-17	GlaxoSmithKline	Regulatory FDA Advisory Committee recommends approval of BREO(TM) ELLIPTA(TM) for the treatment of COPD gsk.com ↗ This positive recommendation is a crucial first step towards making BREO ELLIPTA available for appropriate COPD patients across the US.
2012-03-23	GlaxoSmithKline	Results GSK and Theravance announce completion of the Relovair™* registrational programme and topline results from Relovair™ vs. Advair® phase III studies in COPD gsk.com ↗ In addition, results from two studies for the once-daily investigational medicine Relovair™ (fluticasone furoate “FF”/vilanterol “VI” (FF/VI)) in patients with chronic obstructive pulmonary disease (COPD) and results from a study to evaluate the efficacy and safety of FF and FP (fluticasone propionate) compared to placebo in the treatment of persistent asthma in adults and adolescents were announced.
2011-06-02	GlaxoSmithKline	Results GSK and Theravance announce results of two pivotal Phase III studies for Relovair in COPD gsk.com ↗
2010-09-21	GlaxoSmithKline	Results GSK and Theravance announce combination ICS/LABA Phase II results in the Relovair™ development programme gsk.com ↗ The most common adverse events (FFVI; placebo) were nasopharyngitis (18%;15%), headache (15%; 5%), dizziness (5%; 5%) and candidiasis (8%;0%).
2009-02-03	GlaxoSmithKline	Results GSK and Theravance announce positive phase 2b results for once-daily fluticasone furoate in the treatment of asthma gsk.com ↗

All press releases naming this drug 39 releases

Date	Issuer	Release
2026-01-23	GlaxoSmithKline	Trelegy Ellipta approved in China for use in adults with uncontrolled asthma gsk.com ↗
2020-09-09	GlaxoSmithKline	FDA approves Trelegy Ellipta as the first once-daily single inhaler triple therapy for the treatment of both asthma and COPD in the US gsk.com ↗
2020-02-27	GlaxoSmithKline	GSK filing accepted by European Medicines Agency for Trelegy Ellipta use in adult patients with asthma gsk.com ↗
2018-05-29	GlaxoSmithKline	GSK submits regulatory application in Japan for once-daily single inhaler triple therapy FF/UMEC/VI for patients with COPD gsk.com ↗
2018-05-21	GlaxoSmithKline	GSK receives US approval of Arnuity Ellipta for use in children from 5 years old who suffer from asthma gsk.com ↗
2018-04-18	GlaxoSmithKline	Landmark IMPACT study published in NEJM shows significant benefits of Trelegy Ellipta for patients with COPD gsk.com ↗
2018-03-08	GlaxoSmithKline	GSK announces positive EU approval for labelling update to Relvar Ellipta in patients with asthma gsk.com ↗
2018-02-15	Theravance Biopharma	Theravance Biopharma Highlights Submission of Landmark IMPACT Data to EMA to Support Expanded Label for Trelegy Ellipta theravance.com ↗
2018-01-26	GlaxoSmithKline	GSK announces CHMP positive opinion for labelling update to Relvar Ellipta in patients with asthma gsk.com ↗
2017-12-21	GlaxoSmithKline	FDA approves US label update on ICS/LABA combinations in asthma, based on review of safety data gsk.com ↗
2017-09-20	GlaxoSmithKline	GSK and Innoviva report positive headline results from IMPACT study showing single inhaler triple therapy Trelegy Ellipta reduced COPD exacerbations gsk.com ↗
2017-09-15	GlaxoSmithKline	Trelegy Ellipta once-daily single inhaler triple therapy receives positive opinion from the CHMP in Europe for appropriate patients with COPD gsk.com ↗
2017-09-11	GlaxoSmithKline	Positive results from pioneering Salford Lung Study in asthma published in The Lancet, and presented at European Respiratory Congress gsk.com ↗
2017-07-24	GlaxoSmithKline	GSK submits US regulatory filing of Arnuity Ellipta in children with asthma gsk.com ↗
2017-05-05	GlaxoSmithKline	Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care gsk.com ↗
2017-02-23	GlaxoSmithKline	Positive results for Relvar® Ellipta® lung function study in patients with well-controlled asthma gsk.com ↗
2016-12-02	GlaxoSmithKline	Relvar® Ellipta® 100/25 mcg gains approval in Japan for use in patients with COPD gsk.com ↗
2016-09-06	GlaxoSmithKline	GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress gsk.com ↗
2016-09-04	GlaxoSmithKline	GSK announce positive results from the COPD Salford Lung Study published in the NEJM and presented at European Respiratory Congress gsk.com ↗
2016-06-20	GlaxoSmithKline	FULFIL study shows superiority of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in improving lung function and health-related quality of life in COPD patients gsk.com ↗
2016-05-24	GlaxoSmithKline	Salford Lung Study results show COPD patients treated with Relvar® Ellipta® achieve superior reduction in exacerbations compared with ‘usual care’ gsk.com ↗
2015-09-24	GlaxoSmithKline	Regulatory update: GSK and Theravance announce intention to file Relvar® Ellipta® for COPD in Japan gsk.com ↗
2015-04-30	GlaxoSmithKline	FDA approves BREO® ELLIPTA® for the treatment of adults with asthma in the US gsk.com ↗
2015-03-19	GlaxoSmithKline	GSK and Theravance announce outcome of US FDA Advisory Committee on BREO® ELLIPTA® in asthma gsk.com ↗
2014-09-08	GlaxoSmithKline	GSK data presented at ERS demonstrate potential of blood eosinophil levels to help inform COPD treatment decisions gsk.com ↗
2014-08-20	GlaxoSmithKline	GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the USA for the treatment of asthma gsk.com ↗
2014-06-30	GlaxoSmithKline	GSK and Theravance announce submission to US regulatory authorities for fluticasone furoate/vilanterol in asthma gsk.com ↗
2014-04-22	GlaxoSmithKline	GSK and Theravance announce phase III study of fluticasone furoate/vilanterol in COPD commenced to support potential future filing in Japan gsk.com ↗
2013-12-06	GlaxoSmithKline	GSK and Theravance announce positive results from pivotal phase III study for fluticasone furoate/vilanterol in asthma gsk.com ↗
2013-11-18	GlaxoSmithKline	RELVAR® ELLIPTA® receives European marketing authorisation for the treatment of asthma and COPD gsk.com ↗
2013-10-23	GlaxoSmithKline	GSK announces US regulatory submission for fluticasone furoate monotherapy for asthma gsk.com ↗
2013-09-20	GlaxoSmithKline	RELVAR™ ELLIPTA™ gains approval in Japan for the treatment of asthma gsk.com ↗
2013-07-12	GlaxoSmithKline	Regulatory update: fluticasone furoate/vilanterol submission in Japan gsk.com ↗
2013-05-10	GlaxoSmithKline	BREO™ ELLIPTA™ gains US approval for the treatment of COPD gsk.com ↗
2013-04-17	GlaxoSmithKline	FDA Advisory Committee recommends approval of BREO(TM) ELLIPTA(TM) for the treatment of COPD gsk.com ↗
2012-03-23	GlaxoSmithKline	GSK and Theravance announce completion of the Relovair™* registrational programme and topline results from Relovair™ vs. Advair® phase III studies in COPD gsk.com ↗
2011-06-02	GlaxoSmithKline	GSK and Theravance announce results of two pivotal Phase III studies for Relovair in COPD gsk.com ↗
2010-09-21	GlaxoSmithKline	GSK and Theravance announce combination ICS/LABA Phase II results in the Relovair™ development programme gsk.com ↗
2009-02-03	GlaxoSmithKline	GSK and Theravance announce positive phase 2b results for once-daily fluticasone furoate in the treatment of asthma gsk.com ↗

Evidence & citations 12 cited values

Every value below carries the sentence it was read from. 167 sources stand behind the page.

Field	Value	Cited text
Known as	fluticasone furoate	“We present the protocol for the ongoing INTREPID (INvestigation of TRelegy Effectiveness: usual PractIce Design; ClinicalTrials.gov identifier: NCT03467425) study, a...” PMID 31720293 ↗ Nov 2019 139 “An Open Label, Part-randomised, Four-way Crossover, Single and Repeat Dose Study to Determine the Dose Proportionality and Absolute Bioavailability of Fluticasone Furoate (FF)...” NCT01669070 ↗ “The purpose of this study is to assess the safety and efficacy of fluticasone furoate nasal spray (FFNS), without the use of an antibiotic, in the treatment of adult and...” NCT01018030 ↗ “The study aim was to investigate the pharmacokinetics of single high doses and repeated therapeutic doses of fluticasone furoate (FF) and batefenterol (BAT; a bifunctional...” PMID 30070770 ↗ Aug 2018 “A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation...” NCT01706328 ↗ “A 12-week, Prospective, Open Label, Single Cohort Study to Evaluate the Real-world Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler...” NCT05535972 ↗ “Participants will inhale a LABA (vilanterol (25mcg)) + LAMA (umeclidinium (62.5mcg))+ Inhaled Corticosteroid (ICS; fluticasone furoate (100mcg)) medication once daily for 28+...” NCT06552364 ↗ “Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol...” NCT03376932 ↗ “pharmacokinetics of fluticasone furoate (FF), umeclidinium (UMEC), and vilanterol (VI) in patients with chronic obstructive pulmonary disease (COPD) when administered as a...” PMID 31321713 ↗ Jan 2020 “Subjects in group A (study) will be treated with Fluticasone Furoate nasal: (50 micrograms/spray) 100 micrograms (2 sprays) in each nostril twice daily plus oral montelukast...” NCT05381207 ↗ “A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic...” NCT03474081 ↗ Show 129 more sources
Known as	ALLERMIST	“FF is approved worldwide (including the US, EU and Japan) as an intranasal steroid for the treatment of allergic rhinitis (VERAMYST™ /AVAMYS™ /ALLERMIST™).” NCT01000597 ↗
Known as	Avamys	“FF is approved worldwide (including the US, EU and Japan) as an intranasal steroid for the treatment of allergic rhinitis (VERAMYST™ /AVAMYS™ /ALLERMIST™).” NCT01000597 ↗ 2 “AVAMYS (TM) (fluticasone furoate aqueous nasal spray 100mcg) has been shown having effects on nasal symptoms of seasonal and perennial allergic rhinitis” NCT01270958 ↗ “Montelukast 4mg 1 tablet HS AVAMYS nasal spray 27.5μg QD” NCT04621513 ↗
Known as	AVAMYS (TM)	“AVAMYS (TM) (fluticasone furoate aqueous nasal spray 100mcg) has been shown having effects on nasal symptoms of seasonal and perennial allergic rhinitis” NCT01270958 ↗
Known as	FFNS	“The purpose of this study is to assess the safety and efficacy of fluticasone furoate nasal spray (FFNS), without the use of an antibiotic, in the treatment of adult and...” NCT01018030 ↗ 5 “Fluticasone furoate nasal spray (FFNS) is a novel, enhanced-affinity intranasal corticosteroid administered for the management of allergic rhinitis (AR).” PMID 21888757 ↗ Aug 2011 “The effect of fluticasone furoate nasal spray (FFNS) on growth in prepubescent children has not been evaluated.” PMID 25017530 ↗ May 2014 “Fluticasone Furoate Nasal Sprays (FFNS) 55 Microgram (mcg) and 110 mcg” NCT02424539 ↗ “fluticasone furoate nasal spray \[FFNS\]” NCT00609674 ↗ NCT00519636 ↗
Known as	Fluticasone furoate nasal spray	“an intranasal corticosteroid (fluticasone furoate nasal spray” NCT00609674 ↗ 2 “fluticasone furoate nasal spray 110ug, once daily” NCT01231464 ↗ “fluticasone furoate nasal spray” NCT00539006 ↗
Known as	GW685698	“A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)” NCT01551758 ↗ 5 “fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI)” NCT01395888 ↗ “Fluticasone furoate (FF, GW685698) is a novel once daily inhaled corticosteroid (ICS)” NCT01453023 ↗ “Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder” NCT02446418 ↗ “Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) Inhalation Powder” NCT01706198 ↗ “GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)” NCT01498679 ↗
Known as	GW685698X	“GW685698X (fluticasone furoate) 100mcg Morning” NCT01499446 ↗ 23 NCT00522678 ↗ NCT00398645 ↗ NCT00116883 ↗ NCT00108914 ↗ NCT00116818 ↗ NCT00103454 ↗ NCT00197262 ↗ NCT00109486 ↗ NCT00117325 ↗ NCT00419237 ↗ Show 13 more sources
Known as	VERAMYST	“FF is approved worldwide (including the US, EU and Japan) as an intranasal steroid for the treatment of allergic rhinitis (VERAMYST™ /AVAMYS™ /ALLERMIST™).” NCT01000597 ↗ 2 “Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray” NCT01279057 ↗ “Fluticasone Furoate Nasal Spray (Veramyst)” NCT01076439 ↗
Action	Activate	“GW685698X is a novel glucocorticoid receptor agonist” NCT00522678 ↗
Modality	Other / unclassified	“intranasal steroid inhibits the nasal ocular reflex” PMID 23406601 ↗ Jan 2013
Route	Intranasal	“Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg” NCT00103454 ↗